# Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT00153933** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 58 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** CC-5013

## Key facts

- **NCT ID:** NCT00153933
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-01-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00153933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00153933, "Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00153933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*